Investor Presentaiton
Strong business momentum
Diversified portfolio growth 3
Efficient compounding engine
Sustainable long-term growth
Development-stage pipeline includes many potential launches...
Adjusted Cash Receipts (1) ("top-line")
Development-stage therapy candidates
Therapy
Omecamtiv
Marketer(s)
Cytokinetics
Indication(s)
Potential
launch(2)
Heart failure
2022
Incl. gantenerumab
Zavegepant
Biohaven/Pfizer
Migraine
2023
PT027
AstraZeneca
Asthma
2023
Otilimab
GlaxoSmithKline
Rheumatoid arthritis
2023
Seltorexant
J&J
MDD w/ insomnia
symptoms
2023
Aficamten
Cytokinetics
OHCM
2024
BCX9930
BioCryst
PNH
2025
$50 - 100m
Pelabresib
MorphoSys
Myelofibrosis
2025
CPI-0209
MorphoSys
Blood cancer and solid
tumors
2025+
excl.
gantenerumab
Gantenerumab
(incl. brain shuttle)
Roche
Alzheimer's disease
2023 / 2024
10 potential launches through '25
(gantenerumab excluded from guidance)
$0
2020
2025e
ROYALTY PHARMA
MDD: Major depressive disorder; oHCM: Obstructive hypertrophic cardiomyopathy; PNH: Paroxysmal nocturnal hemoglobinuria.
1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook.
2. All products are in Phase 3 development except: PT027 (ready to file), zavegepant (ready to file) and omecamtiv (filed); based on company disclosures and consensus sales estimates from Visible
Alpha as of May 9, 2022.
42
92View entire presentation